Almirall and the Centre for Genomic Regulation (CRG) Advance Research on Atopic Dermatitis
The research objectives of this collaboration include the characterization of experimental models of AD to identity those with higher physiological relevance and disease predictability.
Atopic dermatitis (AD) is one of the most prevalent skin diseases, affecting approximately 7.2% of adults in Spain and up to 4.4% in Europe. In addition to its frequency, this disease manifests variably, and many patients do not respond satisfactorily to current treatments. To address this need, Almirall and the Centre for Genomic Regulation (CRG) are collaborating closely with the aim to better understand the disease and develop more effective drugs for AD.
Eduard Sabidó, Head of the CRG/UPF Proteomics Unit, and Mercè Pont, Translational Medicine Principal Scientist at Almirall, discussed the progress of their collaboration and the challenges in developing treatments for AD at an event held at the CRG this month during the Open Administration Week.
The research objectives of this collaboration include the characterization of experimental models of AD to identity those with higher physiological relevance and disease predictability. The collaboration aims to generate new data on the mechanisms of action of this complex disease to identify new therapeutic approaches and options for the treatment of AD.
In this collaboration the CRG/UPF Proteomics Unit plays a fundamental with their expert knowledge on proteomic methodologies to characterize the DA models and the changes that happen in the skin of AD patients. Almirall contributes with its expertise in DA, the experimental models and skin samples that will be characterized in depth.
“We are pleased with the recent advancements in the treatment options for atopic dermatitis. However, we are also looking ahead to identify scientific and technological innovations that could enable the next level of treatment options to serve patients even better in the future. This collaboration allows us to combine our expertise in medical dermatology with the capabilities of the CRG's proteomics unit to better understand this complex disease and explore novel treatment opportunities for AD,” states Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall.